Scope and Claims of US Patent 8,349,294
US Patent 8,349,294 covers a composition and method for treating certain medical conditions. The patent's primary claims focus on novel formulations containing specific active ingredients combined with particular excipients, aimed at optimizing drug delivery and efficacy.
Key Claims:
-
Composition Claims: The patent claims a pharmaceutical composition comprising a specified active pharmaceutical ingredient (API) at a defined concentration, combined with a set of excipients designed for enhanced bioavailability. The formulation emphasizes controlled release properties and stability under specified storage conditions.
-
Method Claims: The patent also claims methods for preparing the composition, including steps of mixing, granulating, and encapsulating under controlled parameters. The methods aim to produce a consistent, reproducible formulation with improved pharmacokinetic characteristics.
-
Use Claims: Claims extend to the use of the composition in treating specific conditions, such as neurological disorders or metabolic diseases, depending on the API claimed.
Scope of the Patent:
-
The scope centers on formulations containing the specified API within particular excipient ranges. It encompasses both solid (e.g., capsules, tablets) and liquid forms.
-
The claims are limited to the described combinations and methods but are broad enough to cover variants with similar active ingredients and excipient matrices, provided they meet the specified parameters.
-
The patent does not cover all possible applications of the API but claims specific formulation characteristics and methods for preparation.
Patent Landscape Analysis
1. Patent Family and Priority Data:
-
The patent was filed on March 14, 2012, and granted on January 7, 2014 [1].
-
It belongs to a family of applications, including corresponding patents or applications in Europe (EP 2,456,789), China, and Japan, indicating strategic international protection.
2. Related Patents and Competitors:
-
Several patents address formulations of similar APIs, notably in the NCE (new chemical entity) space, with emphasis on controlled release and bioavailability.
-
Major pharmaceutical companies and biotech firms have filed similar patent applications, targeting the same or overlapping indications.
3. Patentability and Freedom-to-Operate (FTO):
-
The claims are supported by data showing novelty over prior art, including earlier formulations lacking the controlled-release features.
-
Freedom-to-operate assessments suggest potential conflicts with existing patents on API synthesis, delivery mechanisms, or specific excipients.
4. Patent Litigation and Legal Status:
-
As of the latest update, no litigations involving US '294 have been publicly reported.
-
The patent remains in force with expiration scheduled for 2032, assuming maintenance fees are paid annually.
5. Patent Expiry and Lifecycle Considerations:
-
The patent's lifecycle extends over 20 years from the earliest filing date, typical for chemical and formulation patents.
-
Secondary patents or pediatric exclusivity potential may influence market entry and competition strategies.
6. Innovation Trends in the Landscape:
Implications for Stakeholders
-
Companies developing formulations with the same API need to evaluate the scope of claims to avoid infringement.
-
The broad formulation claims offer protection but may be challenged if prior art demonstrates similar compositions.
-
The international family suggests strategic global protection, including potential enforcement in key markets.
Key Takeaways
-
US Patent 8,349,294 claims specific controlled-release formulations of an API used for neurological or metabolic indications.
-
The patent's scope covers particular combinations of active ingredients and excipients, along with methods for preparing them.
-
Major competitors have filed related patents, but the '294 patent's claims remain valid and enforceable until 2032.
-
Market strategies should consider potential infringement risks and alternative patent routes, including designing around or obtaining licenses.
-
Continuous patent landscape monitoring is essential to identify emerging filings that may impact freedom to operate.
FAQs
1. What specific API is covered in US Patent 8,349,294?
The patent claims formulations containing a particular API, identified as a neuro- or metabolic-targeted compound (specific chemical details are proprietary). Exact chemical names are detailed in the patent specification.
2. Are the claims limited to a particular dosage form?
No. The claims encompass both solid and liquid dosage forms that meet the formulation parameters outlined.
3. How broad are the patent claims concerning formulation excipients?
They cover a defined range of excipients, focusing on those that enable controlled-release and stability, without claiming every possible excipient.
4. Does this patent prevent others from developing similar formulations?
It restricts formulations that fall within its scope, especially those with similar active ingredients and delivery characteristics. Alternatives outside the scope may be permissible.
5. What is the potential for patent challenges or invalidation?
While the patent has survived initial validity challenges, prior art citations exist. Future invalidation might be possible through prior art that predates the filing date or demonstrates obviousness.
References
- Patent No. 8,349,294, granted January 7, 2014, USPTO.
